Company Overview: AEtarna Zentaris

Industry News

14 Apr

Aeterna Zentaris to Advance Hormone Drug to Phase III Study – Analyst Blog

Aeterna Zentaris Inc. AEZS announced its plans to conduct two studies on its adult growth hormone deficiency (AGHD) candidate, Macrilen, following its meeting with the FDA regarding the new drug application (NDA) for the candidate. The company intends to conduct a confirmatory phase III study to assess the efficacy...

Read more

2 Mar

Aeterna Zentaris to Present at Roth Conference 2015

Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) (the “Company”) today announced that the Company’s Chairman and CEO, David Dodd , will be presenting a corporate overview and update at the 27th Annual Roth Conference on Wednesday, March 11, 2015 , at 11:00 am (Pacific), in the Colonnade Room (Track 4) of the...

Read more

29 Dec

Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”) today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent,...

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address